Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction

被引:325
作者
Gislason, Gunnar H. [1 ]
Jacobsen, Soren
Rasmussen, Jeppe N.
Rasmussen, Soren
Buch, Pernille
Friberg, Jens
Schramm, Tina Ken
Abildstrom, Steen Z.
Kober, Lars
Madsen, Mette
Torp-Pedersen, Christian
机构
[1] Gentofte Univ Hosp, Dept Cardiol, DK-2900 Hellerup, Denmark
[2] Rigshosp, Natl Inst Publ Hlth, Dept Rheumatol, Copenhagen, Denmark
[3] Bispebjerg Hosp, Dept Cardiovasc Med, DK-2400 Copenhagen NV, Denmark
[4] Hvidovre Univ Hosp, Dept Cardiol, Copenhagen, Denmark
[5] Rigshosp, Ctr Heart, Dept Cardiol, DK-2100 Copenhagen, Denmark
关键词
cyclooxygenase-2; inhibitors; drugs; mortality; myocardial infarction; nonsteroidal antiinflammatory drugs;
D O I
10.1161/CIRCULATIONAHA.106.616219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs ( NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established cardiovascular disease is unknown. We analyzed the risk of rehospitalization for acute myocardial infarction (MI) and death related to the use of NSAIDs including selective COX-2 inhibitors in patients with prior MI. Methods and Results-All patients with first-time MI between 1995 and 2002 as well as all prescription claims for NSAIDs after discharge were identified from nationwide Danish administrative registers. The risk of death and rehospitalization for MI associated with the use of selective COX-2 inhibitors and nonselective NSAIDs was studied with the use of multivariable proportional hazards models and case-crossover analysis. A total of 58 432 patients were discharged alive and included in the study; 9773 experienced rehospitalization for MI, and 16 573 died. A total of 5.2% of patients received rofecoxib, 4.3% celecoxib, 17.5% ibuprofen, 10.6% diclofenac, and 12.7% other NSAIDs. For any use of rofecoxib, celecoxib, ibuprofen, diclofenac, and other NSAIDs, the hazard ratios and 95% confidence intervals for death were 2.80 (2.41 to 3.25; for rofecoxib), 2.57 (2.15 to 3.08; for celecoxib), 1.50 (1.36 to 1.67; for ibuprofen), 2.40 (2.09 to 2.80; for diclofenac), and 1.29 (1.16 to 1.43; for other NSAIDS); there were dose-related increases in risk of death for all of the drugs. There were trends for increased risk of rehospitalization for MI associated with the use of both the selective COX-2 inhibitors and the nonselective NSAIDs. Conclusions-Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages increase mortality in patients with previous MI and should therefore be used with particular caution in these patients.
引用
收藏
页码:2906 / 2913
页数:8
相关论文
共 37 条
[1]   Cyclooxygenase inhibition and cardiovascular risk [J].
Antman, EM ;
DeMets, D ;
Loscalzo, J .
CIRCULATION, 2005, 112 (05) :759-770
[2]   Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure [J].
Aw, TJ ;
Haas, SJ ;
Liew, D ;
Krum, H .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) :490-496
[3]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[4]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[5]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[6]   Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J].
Farkouh, ME ;
Kirshner, H ;
Harrington, RA ;
Ruland, S ;
Verheugt, FW ;
Schnitzer, T ;
Burmester, GR ;
Mysler, E ;
Hochberg, MC ;
Doherty, M ;
Ehrsam, E ;
Gitton, X ;
Krammer, G ;
Mellein, B ;
Gimona, A ;
Matchaba, P ;
Hawkey, CJ ;
Chesebro, JH .
LANCET, 2004, 364 (9435) :675-684
[7]   Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction [J].
Fischer, LM ;
Schlienger, RG ;
Matter, CM ;
Jick, H ;
Meier, CR .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (22) :2472-2476
[8]   Prostacyclin protects against elevated blood pressure and cardiac fibrosis [J].
Francois, H ;
Athirakul, K ;
Howell, D ;
Dash, R ;
Mao, L ;
Kim, HS ;
Rockman, HA ;
FitzGerald, GA ;
Koller, BH ;
Coffman, TM .
CELL METABOLISM, 2005, 2 (03) :201-207
[9]   Use of sumatriptan in Denmark in 1994-5: An epidemiological analysis of nationwide prescription data [J].
Gaist, D ;
Andersen, M ;
Aarup, AL ;
Hallas, J ;
Gram, LF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (04) :429-433
[10]   Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction [J].
Gislason, GH ;
Rasmussen, JN ;
Abildstrom, SZ ;
Gadsboll, N ;
Buch, P ;
Friberg, J ;
Rasmussen, S ;
Kober, L ;
Stender, S ;
Madsen, M ;
Torp-Pedersen, C .
EUROPEAN HEART JOURNAL, 2006, 27 (10) :1153-1158